Tag: RSV Prevention
-
Monoclonal Antibodies Shield Infants from RSV: A New Era of Protection
Understanding RSV and the Vulnerable Population Respiratory syncytial virus (RSV) is a common winter respiratory infection that typically presents as a cold-like illness in healthy individuals. Yet, for young infants—especially those under six months—the elderly, and children with certain health conditions, RSV can lead to serious complications requiring hospitalization. In recent years, scientists and clinicians…
-
Monoclonal Antibodies Shield Infants from RSV: A New Line of Defense
What is RSV and why is it a concern for infants? Respiratory syncytial virus (RSV) is a common winter illness that typically causes cold-like symptoms. For many healthy adults, it is a mild inconvenience, but for young infants—especially those under six months—or older adults, RSV can lead to serious breathing difficulties and hospital stays. The…
-
Monoclonal Antibody nirsevimab Beyfortus Shields Children from RSV
New Evidence Supports nirsevimab Beyfortus in RSV Prevention A comprehensive real-world study published in the Journal of Infection highlights the protective role of the long-acting monoclonal antibody nirsevimab, marketed as Beyfortus, against respiratory syncytial virus (RSV) in children. The findings add to the growing body of evidence that this preventive treatment can reduce RSV infections…
-
Bronchiolitis Update: Beyfortus Indication Expanded to 24 Months for Vulnerable Kids
What Beyfortus is and how it works Beyfortus, also known as nirsevimab, is a monoclonal antibody designed to protect young children from severe bronchiolitis caused by respiratory syncytial virus (RSV). Unlike vaccines, Beyfortus provides passive immunity through a single intramuscular injection that covers the upcoming RSV season, reducing the risk of hospitalization for RSV-related illness…
-
Bronchiolitis and Beyfortus: Expanded indication for vulnerable children up to 24 months
Overview: Beyfortus and the fight against RSV bronchiolitis Bronchiolitis is a common respiratory illness in young children, most notably caused by the respiratory syncytial virus (RSV). Protecting vulnerable infants and toddlers from severe RSV infections has long been a priority for pediatric care teams. Beyfortus, the synthetic antibody nirsevimab developed by AstraZeneca and marketed by…
-
Nirsevimab sharply reduces RSV hospitalizations in U.S. infants during 2024-2025 season
Real-world data show strong protection for U.S. infants As the United States navigates the 2024-2025 RSV season, several U.S. health networks published real-world analyses underscoring the protective effect of nirsevimab in infants. Across multiple settings, infants who received the preventive monoclonal antibody before RSV circulation experienced markedly lower rates of RSV-related hospitalizations compared with comparable…